TrialFrontiers in immunology2022

Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study.

Xiaomei Leng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.